These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21953603)

  • 21. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
    Sampaio C; Bronzova J; Hauser RA; Lang AE; Rascol O; van de Witte SV; Theeuwes AA;
    Mov Disord; 2011 Jul; 26(8):1464-76. PubMed ID: 21542016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
    Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
    Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease.
    Parkinson Study Group POETRY Investigators
    Parkinsonism Relat Disord; 2011 Dec; 17(10):757-60. PubMed ID: 21824799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
    Rektorova I; Balaz M; Svatova J; Zarubova K; Honig I; Dostal V; Sedlackova S; Nestrasil I; Mastik J; Bares M; Veliskova J; Dusek L
    Clin Neuropharmacol; 2008; 31(5):261-6. PubMed ID: 18836343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
    Hauser RA; Reichmann H; Lew M; Asgharian A; Makumi C; Shulman KJ
    Int J Neurosci; 2011 May; 121(5):246-53. PubMed ID: 21244307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
    Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
    Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acupuncture therapy for the symptoms of Parkinson's disease.
    Shulman LM; Wen X; Weiner WJ; Bateman D; Minagar A; Duncan R; Konefal J
    Mov Disord; 2002 Jul; 17(4):799-802. PubMed ID: 12210879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R; Koller WC; Trosch RM; Sherry JH;
    J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol for the treatment of psychosis in Parkinson's disease.
    Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
    J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study.
    Costantini A; Pala MI; Grossi E; Mondonico S; Cardelli LE; Jenner C; Proietti S; Colangeli M; Fancellu R
    J Altern Complement Med; 2015 Dec; 21(12):740-7. PubMed ID: 26505466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
    Simuni T; Borushko E; Avram MJ; Miskevics S; Martel A; Zadikoff C; Videnovic A; Weaver FM; Williams K; Surmeier DJ
    Mov Disord; 2010 Dec; 25(16):2863-6. PubMed ID: 20818667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
    Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
    Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caffeine and progression of Parkinson disease.
    Simon DK; Swearingen CJ; Hauser RA; Trugman JM; Aminoff MJ; Singer C; Truong D; Tilley BC;
    Clin Neuropharmacol; 2008; 31(4):189-96. PubMed ID: 18670242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.